RAPT vs. CGON

Last updated Jun 4, 2026

RAPT (RAPT Therapeutics, Inc.) and CGON (CG Oncology, Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.32 correlation, their price movements are largely independent.

Performance

RAPT vs. CGON - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in RAPT Therapeutics, Inc. (RAPT) and CG Oncology, Inc (CGON). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

RAPT

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CGON

• 1D: -2.00%
• 1M: -19.62%
• YTD: 31.07%
• 6M: 27.72%
• 1Y: 103.14%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

RAPT vs. CGON - Yearly Performance Comparison

	2026 (YTD)	2025	2024
RAPT RAPT Therapeutics, Inc.	71.30%	167.96%	-93.40%
CGON CG Oncology, Inc	31.07%	44.77%	-22.84%

Correlation

The correlation between RAPT and CGON is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (All Time) Calculated using the full available price history since Jan 26, 2024	0.32

The correlation between RAPT and CGON shifts across timeframes, from 0.20 (1 year) to 0.32 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap RAPT : $1.56B CGON : $4.60B
EPS RAPT : -$3.92 CGON : -$1.61
PB Ratio RAPT : 10.29 CGON : 4.21
Total Revenue (TTM) RAPT : $0.00 CGON : $5.07M
Gross Profit (TTM) RAPT : -$200.00K CGON : -$2.54M
EBITDA (TTM) RAPT : -$108.01M CGON : -$191.51M

Return for Risk

RAPT vs. CGON — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CGON

CGON Risk / Return Rank: 87
CGON Sharpe Ratio Rank: 86
CGON Sortino Ratio Rank: 86
CGON Omega Ratio Rank: 81
CGON Calmar Ratio Rank: 87
CGON Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RAPT vs. CGON - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for RAPT Therapeutics, Inc. (RAPT) and CG Oncology, Inc (CGON). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	RAPT	CGON	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	1.83	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.28	—

Drawdowns

Drawdown Indicators

	RAPT	CGON	Difference
Max Drawdown Largest peak-to-trough decline	—	-67.47%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-26.46%	—
Current Drawdown Current decline from peak	—	-26.46%	—
Average Drawdown Average peak-to-trough decline	—	-25.94%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	7.63%	—

Volatility

Volatility by Period

	RAPT	CGON	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	14.38%	—
Volatility (6M) Calculated over the trailing 6-month period	—	41.68%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	56.74%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	64.20%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	64.20%	—

Dividends

RAPT vs. CGON - Dividend Comparison

Neither RAPT nor CGON has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both RAPT and CGON in my portfolio?

RAPT and CGON have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.